Radiotherapy with concomitant weekly docetaxel for Stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC Phase II trial.

@article{Calais2004RadiotherapyWC,
  title={Radiotherapy with concomitant weekly docetaxel for Stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC Phase II trial.},
  author={Gilles Calais and {\'E}tienne Bardet and Christian Sire and Marc Alfonsi and Jean Bourhis and B{\'e}atrix Rhein and Jacques Tortochaux and Yooye Tao Kong Man and Hugues Auvray and Pascal Garaud},
  journal={International journal of radiation oncology, biology, physics},
  year={2004},
  volume={58 1},
  pages={161-6}
}
PURPOSE We designed a prospective Phase II clinical trial to evaluate the addition of weekly chemotherapy using Docetaxel during standard radiation therapy in patients with Stages III and IV oropharynx carcinoma. METHODS A total of 63 patients have been entered in a Phase II multicenter trial. Radiotherapy delivered, with conventional fractionation, 70 Gy… CONTINUE READING